FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

nington,	D.C.	20549			

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burde	en								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     ALIMED NA DIM				2. Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. [ CGEM ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
AHMED NADIM				Silver [ Goldin ]							2	Director			10% Ow	ner			
(Last) (First) (Middle)					Date of Earliest Transaction (Month/Day/Year)								Officer (below)	give title		Other (s below)	pecify		
C/O CULLINAN ONCOLOGY, INC.					03/05/2022								President and CEO						
ONE MAIN STREET, SUITE 520																			
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
CAMBRIDGE MA 02142													2	X Form filed by One Reporting Person					
														Form filed by More than One Reporting					
(City)	(Sta	ate) (2	Zip)		Person														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transc Date (Month/L					action 2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)  4. Securities Acquired (A) 4 Disposed Of (D) (Instr. 3, 4 Disposed Of (D) (Instr. 3)				5. Amount Securities Beneficial Owned Fo Reported	Form ly (D) or		: Direct I Indirect E str. 4)	7. Nature of ndirect Beneficial Ownership (Instr. 4)			
								Code V		Amount	(A) or (D)	Price	Transaction	Transaction(s) (Instr. 3 and 4)			1150. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Date, Transac Code (Ir				e s (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		е	7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g e Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	Code V		(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Performance Stock Unit	(1)	03/05/2022			A		215,000		(1)	1	03/05/2025	Common Stock	215,000	\$0.00	215,0	00	D		

## **Explanation of Responses:**

1. Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. The performance stock units vest upon the Issuer's common stock achieving a specified price per share.

## Remarks:

/s/ Jeffrey Trigilio, Attorney-in-

Fact

03/07/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.